58186-45-1

Basic information

• Product Name: Ethyl 3-(3-aMinophenyl)acrylate
• Synonyms: Ethyl 3-(3-aMinophenyl)acrylate;(E)-ethyl 3-(3-aMinophenyl)acrylate;(E)-Methyl 3-(3-aMinophenyl)acrylate;Methyl 3-(3-aminophenyl)acrylate
• CAS NO: 58186-45-1
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 191.22642
• Mol File: 58186-45-1.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Ethyl 3-(3-aMinophenyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-(3-aMinophenyl)acrylate(58186-45-1)
• EPA Substance Registry System: Ethyl 3-(3-aMinophenyl)acrylate(58186-45-1)

Safety Data

• Hazardous Substances Data: 58186-45-1(Hazardous Substances Data)

Usage

General Description

Ethyl 3-(3-aminophenyl)acrylate is a chemical compound with the molecular formula C13H13NO3. It is a yellow crystalline solid that is primarily used as an intermediate for the synthesis of various pharmaceuticals and organic compounds. Ethyl 3-(3-aminophenyl)acrylate is known for its ability to undergo various chemical reactions, including esterification, amidation, and cross-coupling reactions, making it a versatile building block for the production of complex organic molecules. Additionally, this compound exhibits interesting biological properties, making it a potential candidate for drug development. However, it is important to handle this compound with care as it may pose health and safety risks if not properly managed.

Upstream product

• 585-79-5 m-nitrobromobenzene 
• 292638-85-8 acrylic acid methyl ester 
• 626-01-7 3-Iodoaniline 
• 1664-59-1 3-(3-nitrophenyl)acrylic acid methyl ester 
• 645-00-1 m-iodonitrobenzene 
• 99-61-6 3-nitro-benzaldehyde 
• 659-04-1 methyl 3-nitrocinnamate 
• 555-68-0 (E)-3-Nitrocinnamic acid 
• 67-56-1 methanol 
• 1664-56-8 m-aminocinnamic acid 

Downstream Products

• 2115706-15-3 C₃₇H₃₅N₃O₃ 

Relevant articles and documents

4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads

Multitarget drugs are an emerging alternative to combination therapies. In three iterative cycles of design, synthesis, and biological evaluation, we developed a novel type of potent hybrid inhibitors of bromodomain, and extra-terminal (BET) proteins and histone deacetylases (HDACs) based on the BET inhibitor XD14 and well-established HDAC inhibitors. The most promising new hybrids, 49 and 61, displayed submicromolar inhibitory activity against HDAC1-3 and 6, and BRD4(1), and possess potent antileukemia activity. 49 induced apoptosis more effectively than the combination of ricolinostat and birabresib (1:1). The most balanced dual inhibitor, 61, induced significantly more apoptosis than the related control compounds 62 (no BRD4(1) affinity) and 63 (no HDAC inhibition) as well as the 1:1 combination of both. Additionally, 61 was well tolerated in an in vivo zebrafish toxicity model. Overall, our data suggest an advantage of dual HDAC/BET inhibitors over the combination of two single targeted compounds.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

SOLID STATE FORMS OF (2E)-N-HYDROXY-3-[3-(PHENYLSULFAMOYL)PHENYL]PROP-2-ENAMIDE AND PROCESS FOR PREPARATION THEREOF

The Present invention relates to solid state forms of (2E)-N-hydroxy-3-[3-(N-phenyl sulfamoyl)phenyl]prop-2-enamide represented by the following structural formula-1 and process for the preparation thereof.